EU/3/20/2259: Orphan designation for the treatment of pancreatic cancer

2-hydroxy-N,N,N-trimethylethan-1-aminium (Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoate

Overview

On 24 March 2020, orphan designation EU/3/20/2259 was granted by the European Commission to MWB Consulting S.A.R.L., France, for 2-hydroxy-N,N,N-trimethylethan-1-aminium (Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoate (also known as GB1275) for the treatment of pancreatic cancer.

Key facts

Active substance
2-hydroxy-N,N,N-trimethylethan-1-aminium (Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoate
Intended use
Treatment of pancreatic cancer
Orphan designation status
Withdrawn
EU designation number
EU/3/20/2259
Date of designation
24/03/2020
Sponsor

MWB Consulting S.A.R.L.
1 La Cour
50210 Belval
France
Tel. +33 2343 87120
E-mail: regaffairs@mwbconsulting.com

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Update history

DateUpdate
February 2023Please note that this product was withdrawn from the Union Register of orphan medicinal products on request of the Sponsor.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating